Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for in the U.S.

Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic ARC as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging ...